nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—ABCB1—ovarian cancer	0.357	1	CbGaD
Lenalidomide—ABCB1—Topotecan—ovarian cancer	0.0406	0.354	CbGbCtD
Lenalidomide—ABCB1—Vinorelbine—ovarian cancer	0.0286	0.249	CbGbCtD
Lenalidomide—ABCB1—Paclitaxel—ovarian cancer	0.0201	0.175	CbGbCtD
Lenalidomide—ABCB1—Docetaxel—ovarian cancer	0.0145	0.127	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—ovarian cancer	0.0108	0.0945	CbGbCtD
Lenalidomide—TNFSF11—embryo—ovarian cancer	0.00792	0.062	CbGeAlD
Lenalidomide—PTGS2—ovarian follicle—ovarian cancer	0.00762	0.0597	CbGeAlD
Lenalidomide—CDH5—myometrium—ovarian cancer	0.00619	0.0485	CbGeAlD
Lenalidomide—CDH5—embryo—ovarian cancer	0.00596	0.0467	CbGeAlD
Lenalidomide—CDH5—epithelium—ovarian cancer	0.00486	0.0381	CbGeAlD
Lenalidomide—CDH5—uterine cervix—ovarian cancer	0.00482	0.0378	CbGeAlD
Lenalidomide—CDH5—decidua—ovarian cancer	0.00459	0.036	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—ovarian cancer	0.00453	0.0355	CbGeAlD
Lenalidomide—CDH5—endometrium—ovarian cancer	0.00436	0.0342	CbGeAlD
Lenalidomide—CDH5—uterus—ovarian cancer	0.00402	0.0315	CbGeAlD
Lenalidomide—CRBN—myometrium—ovarian cancer	0.00393	0.0308	CbGeAlD
Lenalidomide—TNFSF11—testis—ovarian cancer	0.00387	0.0304	CbGeAlD
Lenalidomide—CRBN—embryo—ovarian cancer	0.00378	0.0297	CbGeAlD
Lenalidomide—CDH5—female reproductive system—ovarian cancer	0.00361	0.0283	CbGeAlD
Lenalidomide—CDH5—bone marrow—ovarian cancer	0.00341	0.0267	CbGeAlD
Lenalidomide—CDH5—female gonad—ovarian cancer	0.00329	0.0257	CbGeAlD
Lenalidomide—CDH5—vagina—ovarian cancer	0.00327	0.0256	CbGeAlD
Lenalidomide—CRBN—uterine cervix—ovarian cancer	0.00306	0.024	CbGeAlD
Lenalidomide—CRBN—decidua—ovarian cancer	0.00292	0.0229	CbGeAlD
Lenalidomide—CDH5—testis—ovarian cancer	0.00291	0.0228	CbGeAlD
Lenalidomide—TNFSF11—lymph node—ovarian cancer	0.00281	0.022	CbGeAlD
Lenalidomide—CRBN—endometrium—ovarian cancer	0.00277	0.0217	CbGeAlD
Lenalidomide—CRBN—gonad—ovarian cancer	0.00257	0.0201	CbGeAlD
Lenalidomide—CRBN—uterus—ovarian cancer	0.00255	0.02	CbGeAlD
Lenalidomide—CRBN—female reproductive system—ovarian cancer	0.00229	0.018	CbGeAlD
Lenalidomide—CRBN—bone marrow—ovarian cancer	0.00217	0.017	CbGeAlD
Lenalidomide—CDH5—lymph node—ovarian cancer	0.00211	0.0166	CbGeAlD
Lenalidomide—CRBN—female gonad—ovarian cancer	0.00209	0.0164	CbGeAlD
Lenalidomide—CRBN—vagina—ovarian cancer	0.00207	0.0163	CbGeAlD
Lenalidomide—CRBN—testis—ovarian cancer	0.00185	0.0145	CbGeAlD
Lenalidomide—CRBN—lymph node—ovarian cancer	0.00134	0.0105	CbGeAlD
Lenalidomide—PTGS2—myometrium—ovarian cancer	0.00107	0.00839	CbGeAlD
Lenalidomide—PTGS2—embryo—ovarian cancer	0.00103	0.00807	CbGeAlD
Lenalidomide—Pomalidomide—ABCB1—ovarian cancer	0.00102	1	CrCbGaD
Lenalidomide—PTGS2—epithelium—ovarian cancer	0.000841	0.00659	CbGeAlD
Lenalidomide—PTGS2—uterine cervix—ovarian cancer	0.000834	0.00653	CbGeAlD
Lenalidomide—PTGS2—endometrium—ovarian cancer	0.000754	0.00591	CbGeAlD
Lenalidomide—PTGS2—uterus—ovarian cancer	0.000695	0.00544	CbGeAlD
Lenalidomide—ABCB1—myometrium—ovarian cancer	0.000663	0.00519	CbGeAlD
Lenalidomide—ABCB1—embryo—ovarian cancer	0.000637	0.00499	CbGeAlD
Lenalidomide—PTGS2—female reproductive system—ovarian cancer	0.000625	0.00489	CbGeAlD
Lenalidomide—PTGS2—bone marrow—ovarian cancer	0.00059	0.00462	CbGeAlD
Lenalidomide—PTGS2—female gonad—ovarian cancer	0.000568	0.00445	CbGeAlD
Lenalidomide—PTGS2—vagina—ovarian cancer	0.000565	0.00443	CbGeAlD
Lenalidomide—ABCB1—epithelium—ovarian cancer	0.00052	0.00408	CbGeAlD
Lenalidomide—ABCB1—uterine cervix—ovarian cancer	0.000516	0.00404	CbGeAlD
Lenalidomide—ABCB1—decidua—ovarian cancer	0.000491	0.00385	CbGeAlD
Lenalidomide—ABCB1—endometrium—ovarian cancer	0.000466	0.00365	CbGeAlD
Lenalidomide—ABCB1—gonad—ovarian cancer	0.000433	0.00339	CbGeAlD
Lenalidomide—ABCB1—uterus—ovarian cancer	0.00043	0.00337	CbGeAlD
Lenalidomide—ABCB1—female reproductive system—ovarian cancer	0.000386	0.00303	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—ovarian cancer	0.000383	0.00372	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—PIK3CD—ovarian cancer	0.000378	0.00367	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PIK3CA—ovarian cancer	0.000373	0.00362	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—ovarian cancer	0.000365	0.00286	CbGeAlD
Lenalidomide—ABCB1—bone marrow—ovarian cancer	0.000365	0.00286	CbGeAlD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000357	0.00346	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BCL9—ovarian cancer	0.000356	0.00345	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PIK3CA—ovarian cancer	0.000352	0.00342	CbGpPWpGaD
Lenalidomide—ABCB1—female gonad—ovarian cancer	0.000352	0.00275	CbGeAlD
Lenalidomide—ABCB1—vagina—ovarian cancer	0.000349	0.00274	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—ovarian cancer	0.000345	0.00335	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000334	0.00324	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—ovarian cancer	0.00033	0.00321	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—ovarian cancer	0.000326	0.00317	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000322	0.00313	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—PIK3CA—ovarian cancer	0.000319	0.0031	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—ovarian cancer	0.000316	0.00307	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—ovarian cancer	0.000312	0.00303	CbGpPWpGaD
Lenalidomide—ABCB1—testis—ovarian cancer	0.000312	0.00244	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—ovarian cancer	0.000305	0.00296	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—ovarian cancer	0.000295	0.00286	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—ovarian cancer	0.000295	0.00286	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—ovarian cancer	0.000288	0.00279	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—DOK1—ovarian cancer	0.000281	0.00273	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—ovarian cancer	0.000279	0.00271	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPP1CC—ovarian cancer	0.000264	0.00257	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—ovarian cancer	0.000264	0.00256	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000262	0.00255	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—ovarian cancer	0.000257	0.00249	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—MAPK3—ovarian cancer	0.000243	0.00236	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	0.000235	0.00228	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—MAPK1—ovarian cancer	0.000231	0.00225	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000228	0.00222	CbGpPWpGaD
Lenalidomide—ABCB1—lymph node—ovarian cancer	0.000226	0.00177	CbGeAlD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000224	0.00218	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	0.000223	0.00217	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—ovarian cancer	0.000215	0.00209	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HDAC6—ovarian cancer	0.0002	0.00195	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—ovarian cancer	0.000198	0.00192	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD1—ovarian cancer	0.000189	0.00184	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000186	0.00181	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—GADD45A—ovarian cancer	0.000184	0.00179	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—ovarian cancer	0.000178	0.00173	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—YAP1—ovarian cancer	0.000177	0.00172	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—XIAP—ovarian cancer	0.000174	0.00169	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	0.00017	0.00165	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMARCA4—ovarian cancer	0.000169	0.00164	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EREG—ovarian cancer	0.000165	0.0016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PGR—ovarian cancer	0.000155	0.0015	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.000152	0.00148	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	0.000146	0.00142	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PARP1—ovarian cancer	0.000144	0.0014	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	0.00014	0.00136	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	0.000139	0.00135	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—ovarian cancer	0.000133	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	0.000127	0.00123	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000125	0.00122	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	0.000125	0.00121	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000119	0.00116	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPP2R1A—ovarian cancer	0.000117	0.00113	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.000116	0.00113	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000115	0.00111	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.000114	0.00111	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.000114	0.00111	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	0.000108	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.000108	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000107	0.00104	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	0.000103	0.000997	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HSD17B6—ovarian cancer	9.88e-05	0.00096	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	9.71e-05	0.000943	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.57e-05	0.00093	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	9.4e-05	0.000913	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	9.4e-05	0.000913	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	9.4e-05	0.000913	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TERT—ovarian cancer	9.27e-05	0.000901	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	9.23e-05	0.000897	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	9.15e-05	0.000889	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	8.97e-05	0.000871	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	8.89e-05	0.000863	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CAV1—ovarian cancer	8.58e-05	0.000833	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ESR1—ovarian cancer	8.27e-05	0.000803	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6ST—ovarian cancer	8.13e-05	0.00079	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	8.12e-05	0.000789	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CHMP4C—ovarian cancer	7.9e-05	0.000768	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	7.85e-05	0.000763	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CG—ovarian cancer	7.81e-05	0.000759	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APC—ovarian cancer	7.81e-05	0.000759	CbGpPWpGaD
Lenalidomide—Haematuria—Epirubicin—ovarian cancer	7.78e-05	0.000262	CcSEcCtD
Lenalidomide—Confusional state—Docetaxel—ovarian cancer	7.78e-05	0.000262	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.73e-05	0.00026	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	7.73e-05	0.00075	CbGpPWpGaD
Lenalidomide—Hepatobiliary disease—Epirubicin—ovarian cancer	7.72e-05	0.00026	CcSEcCtD
Lenalidomide—Oedema—Docetaxel—ovarian cancer	7.72e-05	0.00026	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—ovarian cancer	7.71e-05	0.00026	CcSEcCtD
Lenalidomide—Epistaxis—Epirubicin—ovarian cancer	7.7e-05	0.000259	CcSEcCtD
Lenalidomide—Infection—Docetaxel—ovarian cancer	7.67e-05	0.000258	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—ovarian cancer	7.66e-05	0.000258	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—ovarian cancer	7.66e-05	0.000258	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—ovarian cancer	7.64e-05	0.000257	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—ovarian cancer	7.62e-05	0.000257	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	7.61e-05	0.000739	CbGpPWpGaD
Lenalidomide—Pneumonia—Doxorubicin—ovarian cancer	7.6e-05	0.000256	CcSEcCtD
Lenalidomide—Shock—Docetaxel—ovarian cancer	7.59e-05	0.000256	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NME2—ovarian cancer	7.57e-05	0.000735	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Docetaxel—ovarian cancer	7.57e-05	0.000255	CcSEcCtD
Lenalidomide—Thrombocytopenia—Docetaxel—ovarian cancer	7.56e-05	0.000255	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—ovarian cancer	7.55e-05	0.000254	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—ovarian cancer	7.55e-05	0.000254	CcSEcCtD
Lenalidomide—Tachycardia—Docetaxel—ovarian cancer	7.53e-05	0.000254	CcSEcCtD
Lenalidomide—Feeling abnormal—Paclitaxel—ovarian cancer	7.5e-05	0.000253	CcSEcCtD
Lenalidomide—Skin disorder—Docetaxel—ovarian cancer	7.5e-05	0.000253	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.49e-05	0.000252	CcSEcCtD
Lenalidomide—Bradycardia—Epirubicin—ovarian cancer	7.46e-05	0.000251	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.45e-05	0.000251	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—ovarian cancer	7.42e-05	0.00025	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—ovarian cancer	7.4e-05	0.000249	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—ovarian cancer	7.37e-05	0.000248	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—ovarian cancer	7.36e-05	0.000248	CcSEcCtD
Lenalidomide—Anorexia—Docetaxel—ovarian cancer	7.36e-05	0.000248	CcSEcCtD
Lenalidomide—Rhinitis—Epirubicin—ovarian cancer	7.35e-05	0.000247	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—ovarian cancer	7.34e-05	0.000247	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—ovarian cancer	7.34e-05	0.000247	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	7.34e-05	0.000713	CbGpPWpGaD
Lenalidomide—Hepatitis—Epirubicin—ovarian cancer	7.33e-05	0.000247	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—ovarian cancer	7.33e-05	0.000247	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—ovarian cancer	7.29e-05	0.000246	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—ovarian cancer	7.27e-05	0.000245	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—ovarian cancer	7.24e-05	0.000244	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—ovarian cancer	7.24e-05	0.000244	CcSEcCtD
Lenalidomide—Urticaria—Paclitaxel—ovarian cancer	7.23e-05	0.000244	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—ovarian cancer	7.22e-05	0.000243	CcSEcCtD
Lenalidomide—Hypotension—Docetaxel—ovarian cancer	7.21e-05	0.000243	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—ovarian cancer	7.2e-05	0.000243	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—ovarian cancer	7.2e-05	0.000243	CcSEcCtD
Lenalidomide—Body temperature increased—Paclitaxel—ovarian cancer	7.2e-05	0.000242	CcSEcCtD
Lenalidomide—Abdominal pain—Paclitaxel—ovarian cancer	7.2e-05	0.000242	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	7.2e-05	0.000699	CbGpPWpGaD
Lenalidomide—Urethral disorder—Epirubicin—ovarian cancer	7.18e-05	0.000242	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	7.17e-05	0.000697	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	7.17e-05	0.000696	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	7.17e-05	0.000696	CbGpPWpGaD
Lenalidomide—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.14e-05	0.000241	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—ovarian cancer	7.12e-05	0.00024	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—ovarian cancer	7.09e-05	0.000239	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—ovarian cancer	7.06e-05	0.000238	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—ovarian cancer	7.05e-05	0.000237	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.03e-05	0.000237	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	7.02e-05	0.000682	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	7.01e-05	0.000681	CbGpPWpGaD
Lenalidomide—Insomnia—Docetaxel—ovarian cancer	6.98e-05	0.000235	CcSEcCtD
Lenalidomide—Paraesthesia—Docetaxel—ovarian cancer	6.93e-05	0.000233	CcSEcCtD
Lenalidomide—Erythema multiforme—Epirubicin—ovarian cancer	6.93e-05	0.000233	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—ovarian cancer	6.9e-05	0.000232	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	6.88e-05	0.000669	CbGpPWpGaD
Lenalidomide—Dyspnoea—Docetaxel—ovarian cancer	6.88e-05	0.000232	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PIK3CD—ovarian cancer	6.87e-05	0.000667	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	6.86e-05	0.000667	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—ovarian cancer	6.86e-05	0.000667	CbGpPWpGaD
Lenalidomide—Somnolence—Docetaxel—ovarian cancer	6.86e-05	0.000231	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—ovarian cancer	6.85e-05	0.000666	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BCL9—ovarian cancer	6.85e-05	0.000665	CbGpPWpGaD
Lenalidomide—Eye disorder—Epirubicin—ovarian cancer	6.85e-05	0.000231	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	6.84e-05	0.000664	CbGpPWpGaD
Lenalidomide—Tinnitus—Epirubicin—ovarian cancer	6.83e-05	0.00023	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—ovarian cancer	6.81e-05	0.00023	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—ovarian cancer	6.8e-05	0.000229	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—ovarian cancer	6.8e-05	0.000229	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—ovarian cancer	6.8e-05	0.000229	CcSEcCtD
Lenalidomide—Dyspepsia—Docetaxel—ovarian cancer	6.79e-05	0.000229	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—ovarian cancer	6.78e-05	0.000228	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—ovarian cancer	6.78e-05	0.000228	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	6.78e-05	0.000658	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Doxorubicin—ovarian cancer	6.75e-05	0.000227	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—ovarian cancer	6.73e-05	0.000227	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	6.72e-05	0.000653	CbGpPWpGaD
Lenalidomide—Decreased appetite—Docetaxel—ovarian cancer	6.71e-05	0.000226	CcSEcCtD
Lenalidomide—Hypersensitivity—Paclitaxel—ovarian cancer	6.71e-05	0.000226	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—ovarian cancer	6.7e-05	0.000226	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—ovarian cancer	6.68e-05	0.000225	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	6.67e-05	0.000647	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.66e-05	0.000224	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—ovarian cancer	6.66e-05	0.000224	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—ovarian cancer	6.65e-05	0.000224	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	6.65e-05	0.000646	CbGpPWpGaD
Lenalidomide—Angiopathy—Epirubicin—ovarian cancer	6.65e-05	0.000224	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—ovarian cancer	6.65e-05	0.000224	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	6.64e-05	0.000645	CbGpPWpGaD
Lenalidomide—Immune system disorder—Epirubicin—ovarian cancer	6.62e-05	0.000223	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—ovarian cancer	6.6e-05	0.000222	CcSEcCtD
Lenalidomide—Pain—Docetaxel—ovarian cancer	6.6e-05	0.000222	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—ovarian cancer	6.6e-05	0.000222	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	6.58e-05	0.000639	CbGpPWpGaD
Lenalidomide—Chills—Epirubicin—ovarian cancer	6.58e-05	0.000221	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	6.55e-05	0.000636	CbGpPWpGaD
Lenalidomide—Arrhythmia—Epirubicin—ovarian cancer	6.55e-05	0.00022	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—ovarian cancer	6.53e-05	0.00022	CcSEcCtD
Lenalidomide—Asthenia—Paclitaxel—ovarian cancer	6.53e-05	0.00022	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—ovarian cancer	6.48e-05	0.000218	CcSEcCtD
Lenalidomide—Pruritus—Paclitaxel—ovarian cancer	6.44e-05	0.000217	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.42e-05	0.000624	CbGpPWpGaD
Lenalidomide—Mental disorder—Epirubicin—ovarian cancer	6.42e-05	0.000216	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—ovarian cancer	6.41e-05	0.000216	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—ovarian cancer	6.38e-05	0.000215	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—ovarian cancer	6.38e-05	0.000215	CcSEcCtD
Lenalidomide—Feeling abnormal—Docetaxel—ovarian cancer	6.36e-05	0.000214	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—ovarian cancer	6.34e-05	0.000213	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—ovarian cancer	6.32e-05	0.000213	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Docetaxel—ovarian cancer	6.31e-05	0.000213	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—ovarian cancer	6.29e-05	0.000212	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—ovarian cancer	6.29e-05	0.000212	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—ovarian cancer	6.29e-05	0.000212	CcSEcCtD
Lenalidomide—Tension—Epirubicin—ovarian cancer	6.26e-05	0.000211	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—ovarian cancer	6.25e-05	0.00021	CcSEcCtD
Lenalidomide—Diarrhoea—Paclitaxel—ovarian cancer	6.23e-05	0.00021	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—ovarian cancer	6.2e-05	0.000209	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—ovarian cancer	6.17e-05	0.000208	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—ovarian cancer	6.15e-05	0.000207	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—ovarian cancer	6.13e-05	0.000207	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—ovarian cancer	6.12e-05	0.000206	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—ovarian cancer	6.11e-05	0.000206	CcSEcCtD
Lenalidomide—Body temperature increased—Docetaxel—ovarian cancer	6.1e-05	0.000206	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—ovarian cancer	6.1e-05	0.000206	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—ovarian cancer	6.08e-05	0.000205	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—ovarian cancer	6.07e-05	0.000589	CbGpPWpGaD
Lenalidomide—Arrhythmia—Doxorubicin—ovarian cancer	6.06e-05	0.000204	CcSEcCtD
Lenalidomide—Dizziness—Paclitaxel—ovarian cancer	6.02e-05	0.000203	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—ovarian cancer	6.01e-05	0.000202	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—ovarian cancer	5.99e-05	0.000202	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MTOR—ovarian cancer	5.99e-05	0.000582	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CB—ovarian cancer	5.99e-05	0.000582	CbGpPWpGaD
Lenalidomide—Mental disorder—Doxorubicin—ovarian cancer	5.94e-05	0.0002	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—ovarian cancer	5.92e-05	0.000199	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—ovarian cancer	5.9e-05	0.000199	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—ovarian cancer	5.9e-05	0.000199	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—ovarian cancer	5.9e-05	0.000199	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—ovarian cancer	5.86e-05	0.000197	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	5.82e-05	0.000566	CbGpPWpGaD
Lenalidomide—Flatulence—Doxorubicin—ovarian cancer	5.82e-05	0.000196	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—ovarian cancer	5.79e-05	0.000195	CcSEcCtD
Lenalidomide—Vomiting—Paclitaxel—ovarian cancer	5.79e-05	0.000195	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—ovarian cancer	5.78e-05	0.000195	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—ovarian cancer	5.75e-05	0.000559	CbGpPWpGaD
Lenalidomide—Malaise—Epirubicin—ovarian cancer	5.75e-05	0.000194	CcSEcCtD
Lenalidomide—Rash—Paclitaxel—ovarian cancer	5.74e-05	0.000193	CcSEcCtD
Lenalidomide—Dermatitis—Paclitaxel—ovarian cancer	5.74e-05	0.000193	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—ovarian cancer	5.73e-05	0.000193	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—ovarian cancer	5.73e-05	0.000193	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—ovarian cancer	5.72e-05	0.000193	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—ovarian cancer	5.71e-05	0.000192	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—ovarian cancer	5.71e-05	0.000192	CcSEcCtD
Lenalidomide—Headache—Paclitaxel—ovarian cancer	5.7e-05	0.000192	CcSEcCtD
Lenalidomide—Hypersensitivity—Docetaxel—ovarian cancer	5.69e-05	0.000192	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—ovarian cancer	5.67e-05	0.000191	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	5.65e-05	0.000549	CbGpPWpGaD
Lenalidomide—Palpitations—Epirubicin—ovarian cancer	5.64e-05	0.00019	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	5.64e-05	0.000548	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—ovarian cancer	5.62e-05	0.000546	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Epirubicin—ovarian cancer	5.61e-05	0.000189	CcSEcCtD
Lenalidomide—Cough—Epirubicin—ovarian cancer	5.57e-05	0.000187	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—ovarian cancer	5.56e-05	0.000187	CcSEcCtD
Lenalidomide—Asthenia—Docetaxel—ovarian cancer	5.54e-05	0.000187	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—ovarian cancer	5.51e-05	0.000186	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CASP3—ovarian cancer	5.51e-05	0.000535	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—ovarian cancer	5.5e-05	0.000534	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	5.48e-05	0.000533	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Doxorubicin—ovarian cancer	5.48e-05	0.000184	CcSEcCtD
Lenalidomide—Pruritus—Docetaxel—ovarian cancer	5.46e-05	0.000184	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—ovarian cancer	5.46e-05	0.000184	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—ovarian cancer	5.43e-05	0.000183	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—ovarian cancer	5.43e-05	0.000183	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—ovarian cancer	5.43e-05	0.000183	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—ovarian cancer	5.42e-05	0.000183	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—ovarian cancer	5.41e-05	0.000182	CcSEcCtD
Lenalidomide—Nausea—Paclitaxel—ovarian cancer	5.41e-05	0.000182	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.39e-05	0.000182	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—NME2—ovarian cancer	5.37e-05	0.000521	CbGpPWpGaD
Lenalidomide—Discomfort—Epirubicin—ovarian cancer	5.37e-05	0.000181	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	5.36e-05	0.000521	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	5.36e-05	0.000521	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—ovarian cancer	5.36e-05	0.000521	CbGpPWpGaD
Lenalidomide—Malaise—Doxorubicin—ovarian cancer	5.32e-05	0.000179	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—ovarian cancer	5.31e-05	0.000179	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—ovarian cancer	5.31e-05	0.000516	CbGpPWpGaD
Lenalidomide—Vertigo—Doxorubicin—ovarian cancer	5.3e-05	0.000179	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—ovarian cancer	5.29e-05	0.000178	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—ovarian cancer	5.28e-05	0.000178	CcSEcCtD
Lenalidomide—Diarrhoea—Docetaxel—ovarian cancer	5.28e-05	0.000178	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	5.26e-05	0.000511	CbGpPWpGaD
Lenalidomide—Confusional state—Epirubicin—ovarian cancer	5.25e-05	0.000177	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.24e-05	0.000509	CbGpPWpGaD
Lenalidomide—Palpitations—Doxorubicin—ovarian cancer	5.22e-05	0.000176	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	5.21e-05	0.000506	CbGpPWpGaD
Lenalidomide—Oedema—Epirubicin—ovarian cancer	5.21e-05	0.000175	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MMP9—ovarian cancer	5.2e-05	0.000505	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	5.2e-05	0.000505	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Doxorubicin—ovarian cancer	5.19e-05	0.000175	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—ovarian cancer	5.17e-05	0.000503	CbGpPWpGaD
Lenalidomide—Infection—Epirubicin—ovarian cancer	5.17e-05	0.000174	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—ovarian cancer	5.15e-05	0.000173	CcSEcCtD
Lenalidomide—Shock—Epirubicin—ovarian cancer	5.12e-05	0.000173	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—ovarian cancer	5.11e-05	0.000172	CcSEcCtD
Lenalidomide—Dizziness—Docetaxel—ovarian cancer	5.1e-05	0.000172	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—ovarian cancer	5.1e-05	0.000172	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—ovarian cancer	5.1e-05	0.000172	CcSEcCtD
Lenalidomide—PTGS2—Disease—PPP1CC—ovarian cancer	5.09e-05	0.000495	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	5.08e-05	0.000494	CbGpPWpGaD
Lenalidomide—Tachycardia—Epirubicin—ovarian cancer	5.08e-05	0.000171	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—ovarian cancer	5.06e-05	0.00017	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—ovarian cancer	5.03e-05	0.00017	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—ovarian cancer	5.03e-05	0.000169	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—ovarian cancer	5.03e-05	0.000169	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—ovarian cancer	5.03e-05	0.000169	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—ovarian cancer	5.01e-05	0.000169	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.99e-05	0.000168	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—ovarian cancer	4.96e-05	0.000167	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—ovarian cancer	4.96e-05	0.000167	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—ovarian cancer	4.91e-05	0.000166	CcSEcCtD
Lenalidomide—Vomiting—Docetaxel—ovarian cancer	4.91e-05	0.000165	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CYTB—ovarian cancer	4.88e-05	0.000474	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.87e-05	0.000473	CbGpPWpGaD
Lenalidomide—Rash—Docetaxel—ovarian cancer	4.87e-05	0.000164	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—ovarian cancer	4.86e-05	0.000164	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—ovarian cancer	4.86e-05	0.000164	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—ovarian cancer	4.86e-05	0.000164	CcSEcCtD
Lenalidomide—Headache—Docetaxel—ovarian cancer	4.84e-05	0.000163	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—ovarian cancer	4.82e-05	0.000162	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	4.8e-05	0.000467	CbGpPWpGaD
Lenalidomide—Infection—Doxorubicin—ovarian cancer	4.79e-05	0.000161	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.78e-05	0.000464	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.77e-05	0.000463	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.74e-05	0.00016	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—ovarian cancer	4.74e-05	0.00016	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—ovarian cancer	4.72e-05	0.000159	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—ovarian cancer	4.72e-05	0.000159	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—ovarian cancer	4.71e-05	0.000159	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—ovarian cancer	4.7e-05	0.000158	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—ovarian cancer	4.68e-05	0.000158	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—ovarian cancer	4.67e-05	0.000157	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—ovarian cancer	4.67e-05	0.000454	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Doxorubicin—ovarian cancer	4.66e-05	0.000157	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.65e-05	0.000452	CbGpPWpGaD
Lenalidomide—Dyspnoea—Epirubicin—ovarian cancer	4.64e-05	0.000156	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—ovarian cancer	4.63e-05	0.000156	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—STAT3—ovarian cancer	4.63e-05	0.000449	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRAS—ovarian cancer	4.62e-05	0.000448	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.6e-05	0.000447	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—ovarian cancer	4.59e-05	0.000155	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—ovarian cancer	4.58e-05	0.000154	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—ovarian cancer	4.58e-05	0.000154	CcSEcCtD
Lenalidomide—Decreased appetite—Epirubicin—ovarian cancer	4.53e-05	0.000152	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	4.5e-05	0.000437	CbGpPWpGaD
Lenalidomide—Hypotension—Doxorubicin—ovarian cancer	4.5e-05	0.000152	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.49e-05	0.000151	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—ovarian cancer	4.49e-05	0.000151	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.49e-05	0.000436	CbGpPWpGaD
Lenalidomide—Constipation—Epirubicin—ovarian cancer	4.45e-05	0.00015	CcSEcCtD
Lenalidomide—Pain—Epirubicin—ovarian cancer	4.45e-05	0.00015	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MAPK3—ovarian cancer	4.42e-05	0.000429	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.39e-05	0.000148	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—ovarian cancer	4.36e-05	0.000147	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—ovarian cancer	4.33e-05	0.000146	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—ovarian cancer	4.3e-05	0.000418	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—ovarian cancer	4.29e-05	0.000145	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—ovarian cancer	4.29e-05	0.000145	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	4.29e-05	0.000417	CbGpPWpGaD
Lenalidomide—Somnolence—Doxorubicin—ovarian cancer	4.28e-05	0.000144	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PPP1CC—ovarian cancer	4.26e-05	0.000414	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BRIP1—ovarian cancer	4.26e-05	0.000414	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Epirubicin—ovarian cancer	4.26e-05	0.000143	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—ovarian cancer	4.24e-05	0.000143	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MAPK1—ovarian cancer	4.21e-05	0.000409	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—ovarian cancer	4.2e-05	0.000408	CbGpPWpGaD
Lenalidomide—Decreased appetite—Doxorubicin—ovarian cancer	4.19e-05	0.000141	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.16e-05	0.00014	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—ovarian cancer	4.15e-05	0.00014	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—ovarian cancer	4.14e-05	0.000139	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	4.12e-05	0.0004	CbGpPWpGaD
Lenalidomide—Pain—Doxorubicin—ovarian cancer	4.12e-05	0.000139	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—ovarian cancer	4.12e-05	0.000139	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—ovarian cancer	4.12e-05	0.000139	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—ovarian cancer	4.12e-05	0.000139	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	4.05e-05	0.000394	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—ovarian cancer	3.97e-05	0.000386	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—ovarian cancer	3.97e-05	0.000134	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.94e-05	0.000133	CcSEcCtD
Lenalidomide—PTGS2—Disease—HDAC6—ovarian cancer	3.86e-05	0.000375	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—ovarian cancer	3.84e-05	0.000129	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.83e-05	0.000372	CbGpPWpGaD
Lenalidomide—Urticaria—Doxorubicin—ovarian cancer	3.83e-05	0.000129	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—ovarian cancer	3.81e-05	0.000128	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—ovarian cancer	3.81e-05	0.000128	CcSEcCtD
Lenalidomide—Asthenia—Epirubicin—ovarian cancer	3.74e-05	0.000126	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3.73e-05	0.000362	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.73e-05	0.000362	CbGpPWpGaD
Lenalidomide—Pruritus—Epirubicin—ovarian cancer	3.68e-05	0.000124	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—ovarian cancer	3.65e-05	0.000355	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.65e-05	0.000354	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.65e-05	0.000354	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—ovarian cancer	3.56e-05	0.00012	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—ovarian cancer	3.55e-05	0.00012	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—ovarian cancer	3.53e-05	0.000343	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.47e-05	0.000337	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYTB—ovarian cancer	3.46e-05	0.000336	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—ovarian cancer	3.46e-05	0.000116	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.46e-05	0.000336	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.45e-05	0.000335	CbGpPWpGaD
Lenalidomide—Dizziness—Epirubicin—ovarian cancer	3.44e-05	0.000116	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—ovarian cancer	3.41e-05	0.000115	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3.39e-05	0.000329	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—ovarian cancer	3.38e-05	0.000328	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.35e-05	0.000326	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—XIAP—ovarian cancer	3.35e-05	0.000325	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—ovarian cancer	3.31e-05	0.000111	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	3.3e-05	0.00032	CbGpPWpGaD
Lenalidomide—Diarrhoea—Doxorubicin—ovarian cancer	3.3e-05	0.000111	CcSEcCtD
Lenalidomide—Rash—Epirubicin—ovarian cancer	3.28e-05	0.000111	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—ovarian cancer	3.28e-05	0.00011	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	3.26e-05	0.000317	CbGpPWpGaD
Lenalidomide—Headache—Epirubicin—ovarian cancer	3.26e-05	0.00011	CcSEcCtD
Lenalidomide—PTGS2—Disease—SMARCA4—ovarian cancer	3.26e-05	0.000317	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—ovarian cancer	3.23e-05	0.000314	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—ovarian cancer	3.19e-05	0.000107	CcSEcCtD
Lenalidomide—PTGS2—Disease—EREG—ovarian cancer	3.18e-05	0.000309	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.18e-05	0.000309	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.17e-05	0.000308	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.11e-05	0.000302	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—ovarian cancer	3.09e-05	0.000104	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	3.06e-05	0.000298	CbGpPWpGaD
Lenalidomide—Vomiting—Doxorubicin—ovarian cancer	3.06e-05	0.000103	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—ovarian cancer	3.04e-05	0.000102	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—ovarian cancer	3.03e-05	0.000102	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—PPP1CC—ovarian cancer	3.02e-05	0.000294	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BRIP1—ovarian cancer	3.02e-05	0.000294	CbGpPWpGaD
Lenalidomide—Headache—Doxorubicin—ovarian cancer	3.02e-05	0.000102	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—AKT1—ovarian cancer	2.98e-05	0.00029	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.87e-05	0.000279	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—ovarian cancer	2.86e-05	9.64e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—YAP1—ovarian cancer	2.86e-05	0.000278	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.83e-05	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FASN—ovarian cancer	2.78e-05	0.00027	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PARP1—ovarian cancer	2.77e-05	0.000269	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.72e-05	0.000264	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC2A1—ovarian cancer	2.64e-05	0.000257	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.64e-05	0.000257	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.59e-05	0.000251	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.59e-05	0.000251	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.59e-05	0.000251	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.49e-05	0.000242	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.44e-05	0.000237	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FASN—ovarian cancer	2.33e-05	0.000226	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC5A5—ovarian cancer	2.29e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PPP2R1A—ovarian cancer	2.25e-05	0.000218	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.24e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A1—ovarian cancer	2.21e-05	0.000215	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.17e-05	0.000211	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.17e-05	0.000211	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1B1—ovarian cancer	2.12e-05	0.000206	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—YAP1—ovarian cancer	2.03e-05	0.000197	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPP2R1A—ovarian cancer	1.88e-05	0.000183	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.87e-05	0.000182	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.83e-05	0.000178	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—ovarian cancer	1.79e-05	0.000174	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—ovarian cancer	1.75e-05	0.00017	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—ovarian cancer	1.72e-05	0.000167	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FASN—ovarian cancer	1.65e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CAV1—ovarian cancer	1.65e-05	0.000161	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.63e-05	0.000158	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.57e-05	0.000153	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6ST—ovarian cancer	1.57e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.51e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—ovarian cancer	1.51e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAV1—ovarian cancer	1.38e-05	0.000134	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.33e-05	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—ovarian cancer	1.32e-05	0.000129	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.32e-05	0.000128	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—ovarian cancer	1.26e-05	0.000122	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—ovarian cancer	1.22e-05	0.000118	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—ovarian cancer	1.17e-05	0.000114	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—ovarian cancer	1.15e-05	0.000112	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTOR—ovarian cancer	1.15e-05	0.000112	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—ovarian cancer	1.11e-05	0.000108	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—ovarian cancer	1.08e-05	0.000105	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—ovarian cancer	1.02e-05	9.93e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—ovarian cancer	9.97e-06	9.68e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAV1—ovarian cancer	9.81e-06	9.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—ovarian cancer	9.66e-06	9.38e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—ovarian cancer	8.94e-06	8.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—ovarian cancer	8.91e-06	8.66e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—ovarian cancer	8.89e-06	8.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—ovarian cancer	8.52e-06	8.27e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—ovarian cancer	8.35e-06	8.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—ovarian cancer	8.28e-06	8.04e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK1—ovarian cancer	8.1e-06	7.87e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—ovarian cancer	8.1e-06	7.87e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—ovarian cancer	7.86e-06	7.63e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—ovarian cancer	7.65e-06	7.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—ovarian cancer	7.03e-06	6.83e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—ovarian cancer	6.85e-06	6.65e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—ovarian cancer	6.5e-06	6.32e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—ovarian cancer	6.23e-06	6.05e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—ovarian cancer	5.92e-06	5.75e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—ovarian cancer	5.89e-06	5.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—ovarian cancer	5.74e-06	5.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—ovarian cancer	4.81e-06	4.67e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—ovarian cancer	4.17e-06	4.05e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—ovarian cancer	3.41e-06	3.31e-05	CbGpPWpGaD
